iTeos Therapeutics, Inc.
ITOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 177.9% | -95.3% | -22.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96.5% | 92.9% | 99.7% | 99.8% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -348.1% | -886.5% | 55.4% | 74.6% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -384% | -894.3% | 36.1% | 62.2% |
| EPS Diluted | -3.32 | -3.15 | 2.56 | 5.68 |
| % Growth | -5.4% | -223% | -54.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $1 |